ACN Newswire

Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair Wrap Up Successfully

29 5 月, 2025

- ASGH brought together more than 2,900 participants from 42 countries and regions- Medical Fair attracted some 13,000 buyers from 57 countries and regions- The two flagship events together resulted in over 390 deal-making sessions and more than 660 business matching meetings- Collaboration agreements were signed during the events, covering areas including patient care, diagnostic solutions, innovative medical devices, and medical imagingHONG KONG, May 28, 2025 - (ACN Newswire via SeaPRwire.com) – The fifth Asia Summit on Global Health (ASGH) and the 16th Hong Kong International Medical and Healthcare Fair (Medical Fair), both organised by the Hong Kong Trade Development Council (HKTDC), have drawn to a successful close. As flagship events of International Healthcare Week (IHW), both ASGH and the Medical Fair brought global healthcare stakeholders together, including government officials and organisations, research pioneers, investors, and business leaders. ASGH attracted over 2,900 participants from 42 countries and regions, while the Medical Fair received some 13,000 buyers from 57 countries and regions. Over 390 one-on-one deal-making sessions and more than 660 business matching meetings were arranged, facilitating over 1,000 high-quality collaborations and connections. The IHW continues to foster global exchange and cooperation, putting a spotlight on Hong Kong’s vast potential in healthcare investment and trade, and reinforcing its position as a regional leading medical hub.Dr Peter K N Lam, Chairman of the HKTDC, said: "The Asia Summit on Global Health and the Hong Kong International Medical and Healthcare Fair concluded with outstanding results driving new collaborations and investments, and injecting new momentum into the healthcare industry. The events brought together leaders across government, business, academia, and investment to tackle today’s healthcare challenges, highlighting Hong Kong’s unique advantages as an international innovation and technology hub under its ‘eight centres’ positioning, actively advancing medical technology, connecting global innovation resources, and paving the way for a healthier and more inclusive future."Over 80 industry experts shared insights on healthcare developmentThe two-day ASGH, jointly organised by the HKSAR Government and the HKTDC under the theme ‘Fostering Global Collaboration for a Shared Future’, focused on a wide spectrum of topics including public health, medical technology breakthroughs, healthy ageing and global business and investment collaboration. The event featured more than 80 speakers comprising government officials and organisations, research pioneers, investors, and business leaders from around the world, all contributing valuable insights to advance global well-being.Prof Lo Chung-mau, Secretary for Health of the HKSAR Government, delivered a keynote speech during the Plenary Session I: Shaping a More Equitable and Sustainable Health System. Other distinguished speakers, including Dr Wu Xiaobin, Vice President of China Pharmaceutical Innovation and Research Development Association; Martin Taylor, Representative to China, World Health Organization; Prof Nancy Ip, President of the Hong Kong University of Science and Technology; and Frédéric Rimattei, Special Envoy for International Affairs of the President of French University Hospitals National Association, shared their insights on tackling global healthcare challenges, offering inspiration for the international healthcare community.In Plenary Session II: Fostering Global Collaboration for a Shared Future, speakers engaged in a lively discussion on trends in global healthcare collaboration. Among them was Ambassador George Hara, Group Chairman and CEO of DEFTA Partners and former Special Advisor to the Cabinet Office of the Prime Minister of Japan, who remarked that more advanced technology and new government regulations are needed to reach a compromise between companies' profits and patients' needs.During the Dialogue with Global Pioneer in Health session, Prof John Hardy, Chair of Molecular Biology of Neurological Disease of UCL Queen Square Institute of Neurology, shared his latest research findings and advanced developments in Alzheimer's disease.The summit co-organised sessions under the overarching theme, Shaping the Future of Healthcare, with the Hong Kong University of Science and Technology for the first time. The discussion focused on the potential of AI in healthcare and how innovation could drive breakthroughs in the field. Dr Alex Ng, President of Tencent Healthcare, commented: “One uniqueness of tech companies is that they can be easily distracted by the latest thing. But you do need companies with patience and perseverance to stay in healthcare and make it work.” Prof Graham Cooke, Vice-Dean (Research) Medicine of Imperial College London, also noted that embedding patient needs into healthcare systems is critical, as many innovations fail in translation due to a lack of this focus, with universities playing a key role as innovation drivers.In Beyond ‘Healthy China 2030’: Driving Health Innovation, speakers explored opportunities in the mainland healthcare market. Marc Horn, Executive Vice President of Merck and President of Merck China, highlighted the two-phase approach of "China for China" followed by "China for the globe”, emphasising healthcare collaboration to develop advanced treatments for global benefit. Dr Zhang Lianshan, Executive Vice President of Jiangsu Hengrui Pharmaceuticals Co., Ltd., stated: "We would like to see our health innovation have realisation of its value, not only in China, but also outside of China. That is why we are talking about Globalisation, where we can achieve maximum value."With growing global attention on healthy ageing, the summit introduced a dedicated Silver Health Chapter. A highlight was the thematic session titled Surfing the Silver Tsunami: Advancements in Geriatrics and Longevity Technology, where Prof Jean Woo, Director of Chinese University of Hong Kong Jockey Club Institute of Ageing, Prof James L. Kirkland, Director of Cedars-Sinai’s Centre for Advanced Gerotherapeutics, and fellow experts explored both the challenges and opportunities posed by ageing populations. Prof Jean Woo highlighted that rapid population ageing is reshaping the global healthcare and socioeconomic landscape. As a city with one of the world’s longest life expectancies, Hong Kong must take early action to strengthen elderly care policies and better allocate health resources. Prof James L. Kirkland also noted that geriatricians ultimately aim to help patients with multiple illnesses reduce medication use while treating their conditions more effectively, enhancing their overall quality of life.Over 390 deal-making sessions and cooperation agreements open new global opportunitiesA key feature of the summit was the ASGH Deal-Making session, which facilitated one-on-one meetings both online and offline, aiming to connect investors and projects in the healthcare sector from around the world to promote global collaborations. Investment projects spanned pharmaceuticals, medical devices and diagnostics, smart healthcare, and community health and wellness and more than 390 one-on-one meetings were successfully arranged for angel investors, venture capitalists, corporate venture arms, private equity firms and family offices.The summit facilitated the signing of cooperation agreements, such as those between Gleneagles Hospital Hong Kong and Emerging Viral Diagnostics, and a tripartite collaboration with PanopticAI and SmartCare, HKSH Medical Group and United Imaging Healthcare, China Resources Guangdong Pharmaceuticals and Hong Kong Medtech Association, Hugobiotech and Bridgeway Healthcare Technology, Canossa Hospital and KA Imaging, and others. These agreements covered diverse healthcare areas, including patient care, diagnostic solutions, innovative medical devices, medical imaging and more. Under the tripartite collaboration agreement between Gleneagles Hospital Hong Kong, PanopticAI, and SmartCare, the integration of PanopticAI’s camera-based vital signs monitoring technology and SmartCare’s patient-centered consultation platform will be implemented into Gleneagles clinic in the future.In addition to its discussion sessions, the summit also featured the ASGH Business Hub, showcasing more than 170 innovative technology companies related to the healthcare industry from 13 countries and regions, including the mainland (Shanghai and Xiamen), Australia, and Thailand, presenting projects and solutions across key areas such as medical innovation, smart healthcare, AI, big data, telemedicine, and cybersecurity. Zhong Wei, Co-founder of Mitrassist Lifesciences, joined the Shanghai Pavilion and said that ASGH helped them bring non-invasive medical monitoring technologies to Southeast Asia, Africa, and other Belt and Road Initiative countries.Medical Fair Drives Industry Innovation and Fosters Business CollaborationThe Medical Fair, organised by the HKTDC and co-organised by the Hong Kong MedTech Association, was held alongside ASGH. The Association—formerly known as the Hong Kong Medical and Healthcare Device Industries Association—held a renaming ceremony during the fair, showcasing the deep integration of medical technology and the industry.The fair brought together some 300 exhibitors from 13 countries and regions, featuring first-time pavilions from the United Kingdom, Thailand and Israel, along with debut exhibitors from Singapore, Germany, Italy and Luxembourg. In addition, seven local universities, over 30 innovative technology companies at the Hong Kong Science and Technology Parks pavilion, and more than 20 medical enterprises brought by the Hong Kong MedTech Association participated. The Hong Kong Council of Social Service also participated in the fair for the first time. Under the theme Innovations Boosting Smart Health Experience, the exhibition spotlighted three major areas: MedTech, GeronTech and green solutions, with many exhibits featuring applications of AI.Many exhibitors and buyers successfully expanded their networks and forged new partnerships at the exhibition. Among them was Hong Kong exhibitor Eieling Technology, a company founded to commercialise research outcomes from the Hong Kong Polytechnic University. The firm showcased its non-invasive liver examination technology, which utilises transient elastography technology. Co-founder and CEO Xiaojia Jia noted that only about four companies worldwide possess this technology, making it a major draw for buyers. "During the exhibition, we received intention orders worth several million Hong Kong dollars from mainland China, Hong Kong, Indonesia, and Thailand, involving around ten devices. This is our third year participating, and we've observed a significant rise in buyers' professionalism during our discussions. We look forward to exhibiting again next year."Karel Lee, CEO of Neoneco from Korea, sourced innovative medical products at the fair with a minimum budget of USD100,000 and he has already identified RhinoCare, an exhibitor from the Israeli pavilion, for its nasal decongestion device, and is also interested in a medical examination device from a Hong Kong exhibitor. Lee stated, "The exhibition allows us to meet with exhibitors face-to-face, build trust, and accelerate the decision-making process. The HKTDC’s Click2Match platform also facilitated efficient business matching. I have already connected with ten exhibitors, and another twenty reached out to me after learning about my sourcing needs. This is one of Asia's premium medical sourcing events, and we will definitely return next year."Beyond business deals, insightful forums were arranged during the Medical Fair to give inspiration to industry buyers. These included The Latest Development of Regulatory Collaboration on Medical Devices in the Greater Bay Area, The MedTech Nexus of the Greater Bay Area, co-organised with the Hong Kong MedTech Association, and Fostering Silver Economy, Leading Quality Elderly & Rehabilitation Care Practices, co-organised with the HKCSS. These forums attracted a strong attendance and offered valuable insights into healthcare. Selected sessions are available for replay on the Fair’s website for extended engagement.This year’s Fair continued to adopt the EXHIBITION+ hybrid model. Global exhibitors, industry professionals, and buyers could make use of the Click2Match and explore sourcing opportunities via HKTDC Sourcing (hktdc.com Sourcing). Click2Match will remain available until 4 June.WebsitesInternational Healthcare Week: https://internationalhealthcareweek.hktdc.com/enAsia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/enHong Kong International Medical and Healthcare Fair: https://www.hktdc.com/event/hkmedicalfair/enPhoto download:  https://bit.ly/4kbr9NcThe fifth Asia Summit on Global Health was attended by over 2,900 participants from 42 countries and regionsProf Lo Chung-mau, Secretary for Health of the HKSAR Government, delivered a keynote speech on the first day during the Plenary Session I: Shaping a More Equitable and Sustainable Health SystemProf John Hardy, Chair of Molecular Biology of Neurological Disease at UCL Queen Square Institute of Neurology. As an internationally renowned neurogeneticist, Prof John Hardy has been awarded the Brain Prize for "groundbreaking research on the basis of Alzheimer's disease" and is known as the “father of Alzheimer’s disease genetic studies”. He shared his latest research findings and advanced developments during the Dialogue with Global Pioneer in Health sessionWith growing global attention on healthy ageing, the summit introduced a dedicated Silver Health Chapter for the first time. A highlight was the thematic session titled Surfing the Silver Tsunami: Advancements in Geriatrics and Longevity Technology, where Prof Jean Woo, Director of Chinese University of Hong Kong Jockey Club Institute of Ageing (far left), and fellow experts explore the challenges and opportunities posed by ageing populationsIn addition to its discussion sessions, the summit also featured the ASGH Business Hub, showcasing more than 170 innovative solutions from the healthcare industry across 13 countries and regionsASGH Deal-making facilitated over 390 one-on-one meetings(Front row from the left) Dr Kyle Wong, Chief Executive Officer and Co-founder of PanopticAI Limited, Dr Kenneth Tsang, Regional Chief Executive Officer of IHH Healthcare North Asia and Chief Executive Officer of Gleneagles Hospital Hong Kong, and Dr Justin Cheng, Chief Executive Officer and Co-founder of SmartCare Technology Co Limited signed a tripartite cooperation agreement witnessed by (back row from the left) Prof Nancy Ip, President of The Hong Kong University of Science and Technology, Dr Prem Kumar Nair, Group Chief Executive Officer of IHH Healthcare and Patrick Lau, Deputy Executive Director of Hong Kong Trade Development CouncilThe 16th Hong Kong International Medical and Healthcare Fair attracted some 13,000 buyers from 57 countries and regions who visited the fair for sourcing and procurementThe Hong Kong MedTech Association had a delegation of over 20 companies participating in the fair, attracting strong interest from buyers who engaged with exhibitors to explore business opportunitiesThe United Kingdom pavilion, participating in the Medical Fair for the first time, promoted innovative medical devices, solutions and services from multiple companies at the fairAn expert from the Greater Bay Area Center for Medical Device Evaluation and Inspection of the National Medical Products Administration; Eva Wong, Senior Electronics Engineer, Medical Device Division of Department of Health (pictured); along with SGS-CSTC Standards Technical Services Co., Ltd.’s expert, shared insights at The Latest Development of Regulatory Collaboration on Medical Devices in the Greater Bay Area forumCo-organised by the Hong Kong Council of Social Service, the Fostering Silver Economy, Leading Quality Elderly & Rehabilitation Care Practices forum drew a strong turnout from industry professionalsMedia enquiriesFor enquiries, please contact Yuan Tung Financial Relations Limited:Louise SongTel: (852) 3428 5691Email: lsong@yuantung.com.hkTiffany LeungTel: (852) 3428 2361Email: tleung@yuantung.com.hkHKTDC’s Communications & Public Affairs Department:Asia Summit on Global HealthSharon HaTel: (852) 2584 4575Email: sharon.mt.ha@hktdc.orgKaty WongTel: (852) 2584 4524Email: katy.ky.wong@hktdc.orgJane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgHong Kong International Medical and Healthcare FairKelly ShekTel: (852) 2584 4537Email: kelly.yt.shek@hktdc.orgClayton LauwTel: (852) 2584 4472Email: clayton.y.lauw@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2025 ACN Newswire via SeaPRwire.com.

ACN Newswire

Modern Dental Group’s Thai Subsidiary Hexa Ceram Held 30th Anniversary Celebration and Dental Symposium

29 5 月, 2025

HONG KONG, May 28, 2025 - (ACN Newswire via SeaPRwire.com) – Modern Dental Group Limited (“Modern Dental” or “the Group”, stock code: 03600.HK), a leading global dental prosthetic devices provider, announced the successful launch of the 30th Anniversary Celebration and Symposium “Hexallence Beyond 30: Pioneering Tomorrow’s Dentistry” by its Thai subsidiary Hexa Ceram Dental Laboratory (“Hexa Ceram”) in Bangkok, Thailand on 24th May. As a crucial segment of Modern Dental Group's strategic framework in the Asia-Pacific region, Hexa Ceram's 30th anniversary celebration is not only a milestone for the industry but also marks a new starting point for the collaborative development of both parties.In the 30 years since its establishment in 1995, Hexa Ceram has been committed to promoting innovation in dental technology. By 2023, its local market share reached 29%, making it the top dental laboratory in Thailand. It has become a benchmark company in the dental field in Thailand and Southeast Asia. Themed "Pioneering Tomorrow’s Dentistry", this year's celebration aims to review the technological advancements and industry contributions of the brand over the past 30 years, and to open up a forward-looking vision in dentistry for practitioners through insightful discussions with top-tier scholars globally. The symposium specially invited 300 dentists, 100 VIP customers in the industry, dean from 10 top universities and presidents of dental associations to jointly build a blueprint for the future development of dentistry. At this new milestone, Hexa Ceram is dedicated to delivering high-quality and innovative dental solutions and services continuously. It is committed to expanding the presence in the ASEAN Economic Community, fostering growth and excellence in dental care.The global dental industry is currently undergoing an accelerated transformation from traditional models to precision-driven and intelligent approaches. With Hexa Ceram officially incorporated into the global system of Modern Dental Group, the two parties will continue to strengthen their leadership in the Thai market through technological innovation, resource synergy and integration, and effectively promote the Group's competitiveness in the global dental industry value chain. Looking ahead, the Group will continue to maintain its focus on digital innovation as a catalyst and give full play to the strategic role of Hexa Ceram to build a dental ecosystem network in Southeast Asia. Through international technology integration, service model advancements and global resource collaboration, we strive to elevate oral diagnosis and treatment technology in Southeast Asia and globally, delivering transformative dental solutions.About Modern Dental Group Modern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners, and anti-snoring devices.Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA and MicroDental in the United States, Modern Dental Pacific in Australia and New Zealand, Modern Dental SG in Singapore, Modern Dental TW in Taiwan, and Apex Digital Dental in Malaysia. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 28 countries and serve over 30,000 customers. Copyright 2025 ACN Newswire via SeaPRwire.com.

ACN Newswire

现代牙科集团泰国公司Hexa Ceram举办三十周年庆典暨牙科论坛

29 5 月, 2025

香港，2025年5月28日 - (亚太商讯 via SeaPRwire.com) - 全球领先之义齿器材供应商 - 现代牙科集团有限公司 (简称「现代牙科」或「本集团」，股份代号：03600.HK) 旗下泰国牙科实验室Hexa Ceram Dental Laboratory ("Hexa Ceram") 于5月24日在泰国曼谷举办「Hexallence Beyond 30: Pioneering Tomorrow's Dentistry」30 周年庆典暨学术交流论坛。作为现代牙科集团在亚太区域战略版图的重要落子，Hexa Ceram三十周年庆典不仅是行业共襄盛举的里程碑，更标志着双方协同发展的全新起点。自 1995 年成立至今三十年，Hexa Ceram秉持推动齿科技术革新使命，至2023年当地市占率达29%，为泰国TOP1牙科实验室，已成为泰国及东南亚齿科领域标杆企业。本届庆典以「开拓牙科未来」为主题，旨在回顾品牌三十年技术沉淀与行业贡献，通过全球顶尖学者的巅峰对话，为从业者开启齿科领域的前瞻视野。盛典特邀全球300位牙医、100位业界菁英客户、10所顶尖学府院长及牙科协会主席，共绘齿科发展蓝图。在迎接新的里程碑之际，Hexa Ceram将致力于提供高质量、创新的牙科解决方案和服务，持续扩大在东盟经济共同体中的影响力，促进对牙科产业发展的卓越追求与行业进步。当前全球齿科行业正经历从传统诊疗模式向精准化、智能化的加速转型。随着Hexa Ceram正式纳入现代牙科集团全球体系，双方将通过技术创新驱动与资源协同整合，持续强化在泰国市场的领导地位，并有力推动集团在全球齿科产业价值链中的竞争力。展望未来，集团将持续以数码化创新为引擎，充分发挥Hexa Ceram的战略作用构建辐射东南亚的齿科生态网络。通过技术跨界融合、服务模式革新与全球资源联动，集团致力推进东南亚地区以至全球口腔诊疗技术提升，缔造突破性的齿科解决方案。关于现代牙科集团现代牙科集团有限公司 (股份代号: 03600.HK) 为全球领先的义齿器材供应商、经销商和顾问，专注于发展迅速的义齿行业为客户提供定制式义齿。我们的产品组合大致可分为三类﹕固定义齿器材，例如牙冠及牙桥；活动义齿器材，例如活动义齿；及其他器材，例如正畸类器材、透明牙套、运动防护器及防鼾器。现代牙科集团拥有多个备受称许的全球品牌，包括西欧的Labocast、Permadental及Elysee Dental、中国的洋紫荆牙科器材、香港的现代牙科器材、美国的Modern Dental USA及MicroDental 、澳洲及新西兰的Modern Dental Pacific、新加坡的Modern Dental SG、台湾的 Modern Dental TW及马来西亚的 Apex Digital Dental等。我们提供稳定和优质的产品及卓越的客户服务，令这些公司品牌能茁壮成长。我们于全球超过 28个国家拥有超过 80 家服务中心及服务逾 30,000 名客户。 Copyright 2025 亚太商讯 via SeaPRwire.com.

ACN Newswire

Euro Manganese Closes C$11.2 million (A$12.3 million) Financing

29 5 月, 2025

Highlights Financing included an upsized C$9.8 million (A$10.8 million) Private Placement and an oversubscribed A$1.5 million (C$1.4 million) Share Purchase PlanCompany welcomes the European Bank of Reconstruction and Development and Eric Sprott as significant shareholdersFunds raised to support ongoing development of the Chvaletice Manganese Project and customer engagements to secure additional offtake term sheets and strategic investmentsVancouver, British Columbia--(ACN Newswire via SeaPRwire.com - May 28, 2025) - Euro Manganese Inc. (TSXV) (ASX: EMN) (FSE: E060) (the "Company" or "Euro Manganese") is pleased to announce that, following the approval by its shareholders at its Annual General and Special Meeting held on May 15, 2025 (the "AGSM"), it has closed the previously announced financing package which included: (a) a private placement (the "Placement") of common shares ("New Shares") and CHESS Depositary Interests ("New CDIs" together with the New Shares, "New Securities") in the capital of the Company of C$9.8 million (approximately A$10.8 million); and (b) a Share Purchase Plan ("SPP", together with the Placement, the "Financing") with certain eligible shareholders in the amount of A$1.5 million (approximately C$1.4 million). The Company also announces an option grant to certain directors, officers, employees, and consultants as described below.Martina Blahova, CEO of Euro Manganese, commented:"We are extremely pleased with the strong support demonstrated by both our existing shareholders and new investors, including the notable participation of Mr. Eric Sprott. As Euro Manganese's largest shareholder, EBRD's investment reinforces its support and commitment to the Chvaletice Project. This critical financing enables the Company to pursue certain key milestones and advance project development. We thank shareholders for their ongoing support."The net proceeds of the Financing will be used to support ongoing development of the Chvaletice Manganese Project, including customer engagements to secure additional offtake term sheets and strategic investments, the operation of the demonstration plant, as needed, to market the Company's product to potential customers and to advance permitting.All defined terms in this press release have the same meaning as set out in the press releases dated March 6, 2025 and April 1, 2025, unless such terms are otherwise defined herein.Details of the PlacementThe Placement consisted of the issuance of an aggregate of 54,578,350 New Securities, comprised of 39,671,662 New Shares at a price of C$0.18 per New Share and 14,906,688 New CDIs (with each New CDI representing one New Share) at a price of A$0.195 per New CDI, and 54,578,350 Warrants for aggregate gross proceeds of C$9.8 million (approximately A$10.8 million). Warrants issued in connection with the Placement are exercisable any time prior to November 28, 2026 (Vancouver), and have an exercise price of C$0.225 per New Security. Included in the Placement were:14,650,278 New CDIs and 14,650,278 Warrants subscribed for under the Placement led by the Joint Lead Managers (as defined below);39,463,331 New Shares and 39,463,331 Warrants subscribed for directly with the Company, which included (i) 21,400,000 New Shares and 21,400,000 Warrants subscribed for by the European Bank for Reconstruction and Development ("EBRD") (the "EBRD Subscription"); (ii) 16,666,666 New Shares and 16,666,666 Warrants subscribed for by Mr. Eric Sprott, through 2176423 Ontario Ltd., a corporation which is beneficially owned by Mr. Sprott; and (iii) 1,396,665 New Shares and 1,396,666 Warrants subscribed for by other, non-related investors; andsubscriptions by directors of the Company for 464,741 New Securities (comprised of 208,331 New Shares and 256,410 New CDIs) and 464,741 Warrants (the "Related Party Subscription").As the number of New Securities and Warrants issued under the Placement led by the Joint Lead Managers, pursuant to the EBRD Subscription, and subscribed for directly with the Company exceeded the number of securities permitted to be issued without obtaining prior shareholder approval under Listing Rule 7.1 of the Australian Securities Exchange ("ASX"), the Company was required to seek shareholder approval. Similarly, the Related Party Subscriptions were subject to shareholder approval as required by ASX Listing Rule 10.11.1 and 10.11.4. Resolutions approving these issues were sought and received at the AGSM.Since certain directors and management of the Company participated in the Placement, the Placement is considered to be a related party transaction subject to Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is relying on exemptions from the formal valuation and minority shareholder approval requirements provided under sections 5.5(a) and 5.7(1)(a) of MI 61-101 on the basis that participation in the Placement by such directors and management does not exceed 25% of the fair market value of the Company's market capitalization, as calculated in accordance with MI 61-101.Details of the Share Purchase PlanThe SPP was conducted pursuant to a Prospectus dated April 23, 2025 and was comprised of 7,692,307 New CDIs at a price of A$0.195 per CDI, and 7,692,307 Warrants, for aggregate gross proceeds of A$1.5 million (approximately C$1.4 million). Warrants issued in connection with the SPP are exercisable any time prior to November 28, 2026 (Vancouver), with an exercise price of C$0.225 per New Security.As announced in the Company's news release of May 15, 2025, the SPP was oversubscribed and subscriptions were scaled back to the maximum aggregate amount permitted.As the number of New CDIs and Warrants issued under the SPP exceeded the Company's Placement Capacity under ASX Listing Rule 7.1, the Company was required to seek shareholder approval, such approval having been received at the AGSM.Broker Fees and Additional WarrantsCanaccord Genuity (Australia) Limited ("Canaccord Genuity") and Foster Stockbroking Pty Ltd ("FSB", together with Canaccord Genuity, the "Joint Lead Managers") acted as Joint Lead Managers and Bookrunners for the Financing. Aggregate fees payable in cash by the Company to Canaccord Genuity and FSB in connection with the Financing consisted of A$498,918 (approximately C$454,016).In addition, the Company also issued 4,904,478 broker warrants (the "Broker Warrants") to Canaccord Genuity and FSB, representing 12% of the aggregate number of New Securities issued under the Placement and the SPP, excluding those issued pursuant to the EBRD Subscription. The Broker Warrants are exercisable any time prior to May 28, 2027 (Vancouver), with an exercise price of C$0.225 per New Security.Additionally, as announced previously on March 6, 2025 and April 1, 2025, and in connection with an amendment to the Company's Convertible Loan Royalty Agreement (the "CLRA") with OMRF (BK) LLC ("Orion") the Company has issued 22,263,733 warrants to purchase New Securities (the "Additional Warrants") to Orion, exercisable any time prior to November 28, 2026 (Vancouver), with an exercise price of C$0.225 per New Security. Additional details about the CLRA are available in the news releases of the Company dated December 3, 2024, November 29, 2023 and November 27, 2023.As the number of the Broker Warrants and Additional Warrants exceeded the Company's Placement Capacity under ASX Listing Rule 7.1, the Company was required to seek shareholder approval, such approvals having been received at the AGSM.Applicable Hold PeriodsNew Shares issued or made issuable under the Financing will not be permitted to be traded in or into Canada or through the facilities of the TSX Venture Exchange (the "TSX-V") prior to a four month and one day statutory hold period expiring on September 29, 2025 (Vancouver), and will be subject to legending requirements under Canadian securities laws. New Shares will be listed on the TSX-V and New CDIs listed on the ASX. The Warrants, Broker Warrants and Additional Warrants will not be listed. New CDIs will not be permitted to be exchanged for common shares and traded through the facilities of the TSX-V prior to the four month and one day statutory hold period expiring on September 29, 2025 (Vancouver).The Warrants, Broker Warrants and Additional Warrants will not be listed. Common shares issued upon exercise of the Warrants, Broker Warrants or Additional Warrants prior to September 29, 2025 (Vancouver) are subject to the same restrictions noted above.The Warrants, Broker Warrants or Additional Warrants may not be traded in or into Canada prior to September 29, 2025 (Vancouver) and will be subject to legending requirements under Canadian securities laws.Early Warning Disclosure for The European Bank for Reconstruction and DevelopmentEBRD acquired the 21,400,000 units pursuant to the Placement at a price per unit of C$0.18 for total consideration of C$3,852,000.Prior to the completion of the EBRD Subscription, EBRD owned 3,560,000 common shares, representing an ownership interest of 4.42% of the issued and outstanding common shares of the Company. On completion of the EBRD Subscription, EBRD's ownership interest increased to 24,960,000 common shares, representing an ownership interest of 17.48% of the issued and outstanding common shares and an increase of 13.06%. Assuming the exercise by EBRD of all its Warrants, and assuming the exercise of (i) all Warrants issued under the Placement, (ii) all Warrants issued under the SPP, and (iii) all Additional Warrants, EBRD's ownership interest will be in aggregate 46,360,000 common shares, representing an aggregate beneficial ownership interest of 19.96% of the issued and outstanding shares and an increase of 15.54%. EBRD has agreed, pursuant to the terms of the Warrants issued to EBRD, that for so long as the Company is listed on the TSX-V, unless approval from the TSX-V and disinterested shareholders of the Company have been obtained pursuant to the policies of the TSX-V (provided that such approval is required at the relevant time), EBRD will not be permitted to exercise such number of warrants that would result in it beneficially owning more than 19.99% of the outstanding common shares of the Company.EBRD acquired the New Shares and Warrants for investment purposes. Depending on market conditions and other factors, EBRD may from time to time acquire and/or dispose of securities of the Company or continue to hold its current position.To obtain a copy of the early warning report to be filed by EBRD in connection with this press release, please contact: Michael Zlobin at +44 207338 8981. EBRD's address is 5 Bank Street, London, E14 4BG, United Kingdom.Early Warning Disclosure for Eric SprottEric Sprott, through 2176423 Ontario Ltd., a corporation that is beneficially owned by him acquired 16,666,666 units pursuant to the Placement, at $0.18 per unit for total consideration of C$3,000,000. Prior to the Placement, Mr. Sprott did not beneficially own or control any securities of the Company. As a result of the Placement, Mr. Sprott now beneficially owns 16,666,666 Shares and 16,666,666 Warrants, representing approximately 11.7% of the outstanding Shares on a non-diluted basis and 20.9% of the outstanding Shares on a partially-diluted basis assuming exercise of such Warrants.The securities are held for investment purposes. Mr. Sprott has a long-term view of the investment and may acquire additional securities including on the open market or through private acquisitions or sell the securities including on the open market or through private dispositions in the future depending on market conditions, reformulation of plans and/or other relevant factors.A copy of the early warning report with respect to the foregoing will appear on Euro Manganese's profile on SEDAR+ at www.sedarplus.ca and may also be obtained by calling Mr. Sprott's office at (416) 945-3294 (2176423 Ontario Ltd., 7 King Street East, Suite 1106, Toronto Ontario M5C 3C5).Option GrantThe Company today also granted stock options ("Options") to certain of its directors, officers, employees, and consultants to purchase up to an aggregate of 7,020,000 common shares ("Shares"). Of these, 1,330,000 Options have been granted to directors, 2,530,000 Options have been granted to officers, and 3,160,000 Options have been granted to employees and consultants. The Options are exercisable for a term of ten years at an exercise price of CAD$0.19 per Share. All of the Options will vest one-third immediately and then one third on each of the first and second anniversaries of today's date of grant, except that 1,650,000 of the Options granted to certain officers, employees and consultants will all vest immediately in recognition of such individuals work in managing the successful completion of the oversubscribed Financing.Interim CFOAs announced earlier this month, the Company will be appointing a new Chief Financial Officer ("CFO") in the coming weeks. Until such time, following the departure of Dean Larocque as CFO on May 30, 2025, Martina Blahova will serve as interim CFO.About Euro Manganese Euro Manganese is a battery materials company focused on becoming a leading producer of high-purity manganese for the electric vehicle industry. The Company is advancing development of the Chvaletice Manganese Project in the Czech Republic and an early-stage opportunity to produce battery-grade manganese products in Bécancour, Québec.The Chvaletice Project is a unique waste-to-value recycling and remediation opportunity involving reprocessing old tailings from a decommissioned mine. It is also the only sizable resource of manganese in the European Union, strategically positioning the Company to provide battery supply chains with critical raw materials to support the global shift to a circular, low-carbon economy.Euro Manganese is dual listed on the TSX-V and the ASX.Authorized for release by the CEO of Euro Manganese Inc.Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) or the ASX accepts responsibility for the adequacy or accuracy of this release. Enquiries Martina BlahovaChief Executive Officer+1 (604) 681-1010martina@mn25.caLodeRock AdvisorsNeil WeberInvestor and Media Relations - North America+1 (647) 222-0574 neil.weber@loderockadvisors.comJane Morgan Management Jane Morgan Investor and Media Relations - Australia +61 (0) 405 555 618 jm@janemorganmanagement.com.auCompany Address: #709 -700 West Pender St., Vancouver, British Columbia, Canada, V6C 1G8Website: www.mn25.caFollow us on: LinkedIn | Twitter | YouTubeClick Here to Subscribe to our mailing list for updatesForward-Looking StatementsCertain statements in this news release constitute "forward-looking statements" or "forward-looking information" within the meaning of applicable securities laws. Such statements and information involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the Company, its Chvaletice Project, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. Such statements can be identified by the use of words such as "may", "would", "could", "will", "intend", "expect", "believe", "plan", "anticipate", "estimate", "scheduled", "forecast", "predict" and other similar terminology, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved.Readers are cautioned not to place undue reliance on forward-looking information or statements. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements and, even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company.All forward-looking statements are made based on the Company's current beliefs including various assumptions made by the Company including that the Chvaletice Project will be developed and operate in accordance with current plans, appointment of permanent CFO, that the Company will be able to raise the financing that it requires, and that it will meet conditions of its secured credit facility. Factors that could cause actual results or events to differ materially from current expectations include, among other things: risks and uncertainties related to the Company's ability to meet the conditions of its secured credit facility, risks related to maintaining and securing necessary licenses or permits; risks related to acquisition of surface rights; inability to secure sufficient offtake agreements; the availability of acceptable financing; the potential for unknown or unexpected events to cause contractual conditions to not be satisfied; developments in EV (Electric Vehicles) battery markets and chemistries; and risks related to fluctuations in currency exchange rates, changes in laws or regulations; and regulation by various governmental agencies. For a further discussion of risks relevant to the Company, see "Risk Factors" in the Company's annual information form for the year ended September 30, 2024, available on the Company's SEDAR+ profile at www.sedarplus.ca.Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release and are expressly qualified in their entirety by this cautionary statement. Subject to applicable securities laws, the Company does not assume any obligation to update or revise the forward-looking statements contained herein to reflect events or circumstances occurring after the date of this news release.NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/253771 Copyright 2025 ACN Newswire via SeaPRwire.com.